Form 4: HHLR Advisors and Hillhouse Investment Management Report Sale of BeiGene Shares

HHLR Advisors and Hillhouse Investment Management jointly report the sale of 17,842,500 BeiGene ordinary shares, equivalent to 1,372,500 ADSs, at a price of $200 per ADS.

Summary

• HHLR Advisors, Ltd. and Hillhouse Investment Management, Ltd. have jointly filed a Form 4, reporting a transaction involving BeiGene, Ltd. shares.
• The transaction involved the sale of 17,842,500 ordinary shares, which were in the form of American Depositary Shares (ADSs).
• The sale price was $200 per ADS, with each ADS representing 13 ordinary shares.
• Following the transaction, the reporting entities still beneficially own 125,045,741 ordinary shares.
• The shares are held indirectly through various funds managed by HHLR and HIM.
• HHLR Advisors and Hillhouse Investment Management are under common control and share certain policies, personnel, and resources.

Sentiment

Score: 5

Explanation: The document is a neutral report of a share sale, with no indication of positive or negative sentiment. It is a routine regulatory filing.

Management Comments

• The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise.
• Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.

Industry Context

This filing is a routine disclosure of share transactions by major shareholders, which is common in the biotech industry. It provides transparency into the ownership changes of BeiGene.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and major shareholders in publicly traded companies, including those in the biotech sector.
• The transaction is similar to other large block trades reported by institutional investors in the pharmaceutical and biotech industries.
• The sale of shares by HHLR Advisors and Hillhouse Investment Management is not unusual given their status as significant shareholders.

Stakeholder Impact

• The sale of shares by major shareholders could potentially influence the market perception of BeiGene.
• The transaction may have a minor impact on the share price in the short term.

Key Dates

Keywords

BeiGene, HHLR Advisors, Hillhouse Investment Management, Ordinary Shares, American Depositary Shares, ADS, Share Sale, Form 4, Beneficial Ownership